This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Senesco Technologies Inc. (ELOX) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Senesco Technologies Inc. (ELOX) delivered earnings and revenue surprises of -12.94% and 100%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Are Medical Stocks Lagging Elevation Oncology (ELEV) This Year?
by Zacks Equity Research
Here is how Elevation Oncology, Inc. (ELEV) and Senesco Technologies Inc. (ELOX) have performed compared to their sector so far this year.
Senesco Technologies Inc. (ELOX) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
by Zacks Equity Research
Senesco Technologies Inc. (ELOX) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Biotech Stock Roundup: GILD, BMY's Regulatory News, BLUE's Therapy Approval & More
by Zacks Equity Research
Regulatory and pipeline updates from BMY and GILD are the key highlights from the biotech sector during the past week.
Eloxx (ELOX) Down After Cystic Fibrosis Study Fails to Meet Goal
by Zacks Equity Research
Eloxx Pharmaceuticals' (ELOX) phase II combination study evaluating pipeline candidate ELX-02 in cystic fibrosis fails to achieve statistical significance in efficacy endpoints.
New Strong Sell Stocks for August 24th
by Zacks Equity Research
BGS, FTHM, NTLA, LEVL, and ELOX have been added to the Zacks Rank #5 (Strong Sell) List on August 24, 2021
Are Options Traders Betting on a Big Move in Eloxx Pharmaceuticals (ELOX) Stock?
by Aditi Saraogi
Investors need to pay close attention to Eloxx Pharmaceuticals (ELOX) stock based on the movements in the options market lately.
Is the Options Market Predicting a Spike in Eloxx (ELOX) Stock?
by Zacks Equity Research
Investors need to pay close attention to Eloxx (ELOX) stock based on the movements in the options market lately.
Eloxx Pharmaceuticals (ELOX) Is in Oversold Territory: What's Next?
by Zacks Equity Research
Eloxx Pharmaceuticals (ELOX) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
Eloxx Pharmaceuticals (ELOX) in Focus: Stock Moves 6.9% Higher
by Zacks Equity Research
Eloxx Pharmaceuticals (ELOX) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
The Zacks Analyst Blog Highlights: Eloxx Pharmaceuticals, BGC Partners, SharpSpring, Ra Medical Systems and American States Water
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Eloxx Pharmaceuticals, BGC Partners, SharpSpring, Ra Medical Systems and American States Water
5 Stocks to Gain the Most With the Economy Set to Reopen
by Zacks Equity Research
These five stocks are poised to grow with the guidelines laid out to reopen the economy, as coronavirus pandemic dissipates.
Will Eloxx Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Eloxx.
Eloxx Pharmaceuticals, Inc. (ELOX) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Eloxx Pharmaceuticals, Inc. (ELOX).
Proteostasis Plunges on Weak Data From Cystic Fibrosis Study
by Zacks Equity Research
Proteostasis (PTI) announces data from a phase I study evaluating its triplet combination in cystic fibrosis. Although data were promising, it was weaker than rival Vertex's triplet combinations.